These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25042151)

  • 1. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
    Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Rabinovich GA; Bieche I; Vidaud M; de Gramont A; Martinet M; Cvitkovic E; Faivre S; Raymond E
    Eur J Cancer; 2014 Sep; 50(14):2463-77. PubMed ID: 25042151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib.
    Zucchetti M; Bonezzi K; Frapolli R; Sala F; Borsotti P; Zangarini M; Cvitkovic E; Noel K; Ubezio P; Giavazzi R; D'Incalci M; Taraboletti G
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):879-87. PubMed ID: 23978989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.
    Koonce NA; Griffin RJ; Dings RPM
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29232825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer.
    Gheysen L; Soumoy L; Trelcat A; Verset L; Journe F; Saussez S
    Cells; 2021 May; 10(5):. PubMed ID: 34063063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unraveling galectin-1 as a novel therapeutic target for cancer.
    Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S
    Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.
    Leung Z; Ko FCF; Tey SK; Kwong EML; Mao X; Liu BHM; Ma APY; Fung YME; Che CM; Wong DKH; Lai CL; Ng IO; Yam JWP
    J Exp Clin Cancer Res; 2019 Oct; 38(1):423. PubMed ID: 31640796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment.
    Michael JV; Wurtzel JG; Goldfinger LE
    Anticancer Res; 2016 Oct; 36(10):5053-5061. PubMed ID: 27798864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of galectin-1 inhibitor OTX008 on oral squamous cell carcinoma cells in vitro and the role of AP-1 and the MAPK/ERK pathway.
    Greer PFC; Rich A; Coates DE
    Arch Oral Biol; 2022 Feb; 134():105335. PubMed ID: 34891102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synthetic flavonoid WYC02-9 inhibits cervical cancer cell migration/invasion and angiogenesis via MAPK14 signaling.
    Chen YJ; Cheng YJ; Hung AC; Wu YC; Hou MF; Tyan YC; Yuan SS
    Gynecol Oncol; 2013 Dec; 131(3):734-43. PubMed ID: 24145114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
    Scholz A; Wagner K; Welzel M; Remlinger F; Wiedenmann B; Siemeister G; Rosewicz S; Detjen KM
    Gut; 2009 Feb; 58(2):261-70. PubMed ID: 18829975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.
    Zeng KW; Li N; Dong X; Ma ZZ; Jiang Y; Jin HW; Tu PF
    Eur J Pharmacol; 2013 Aug; 714(1-3):261-73. PubMed ID: 23684542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis, angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C.
    Hu J; Cheng Y; Li Y; Jin Z; Pan Y; Liu G; Fu S; Zhang Y; Feng K; Feng Y
    Eur J Cancer; 2014 Sep; 50(13):2336-50. PubMed ID: 25001183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of two orally bioavailable anti-cancer agents, IRC-110160 and STX140.
    Foster PA; Stengel C; Ali T; Leese MP; Potter BV; Reed MJ; Purohit A; Newman SP
    Anticancer Res; 2008; 28(3A):1483-91. PubMed ID: 18630502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.